TCR2 Therapeutics Inc (TCRR)

[jondoeuk]

While the ORR dropped, PFS and OS data look pretty solid considering late line patients, and suggest responses are durable especially compared to benchmark data.

Once the PhII expansion is initiated they will assess gavo-cel efficacy in four indications (malignant pleural mesothelioma, NSCLC, ovarian and cholangiocarcinoma), evaluate combinations with an anti-PD-1, allow for retreatment on progression or if stable disease, and test alternate mesothelin expression cutoff levels.

In addition, an IND will be filed this year for a second gen version of gavo-cel (which has a cell intrinsic PD-1-CD28 'switch') [1], they are working on other enhancements, including IL-15, dual TRuCs, and even an allo platform [2].

Refs:
1 https://cancerres.aacrjournals.org/content/80/16_Supplement/893
2 https://cancerres.aacrjournals.org/content/80/16_Supplement/2190